Table of Contents Author Guidelines Submit a Manuscript
Journal of Diabetes Research
Volume 2015, Article ID 150176, 10 pages
http://dx.doi.org/10.1155/2015/150176
Review Article

Study of Protein Biomarkers of Diabetes Mellitus Type 2 and Therapy with Vitamin B1

Department of Microbiology and Molecular Genetics, University of the Punjab, Lahore 54590, Pakistan

Received 15 September 2014; Revised 27 January 2015; Accepted 3 February 2015

Academic Editor: Joseph Fomusi Ndisang

Copyright © 2015 Samreen Riaz. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. American Diabetes Association, “Standards of medical care in diabetes—2007,” Diabetes Care, vol. 30, supplement 1, pp. S4–S41, 2007. View at Publisher · View at Google Scholar
  2. American Diabetes Association, “Diagnosis and classification of diabetes mellitus,” Diabetes Care, vol. 30, supplement 1, pp. S42–S47, 2007. View at Publisher · View at Google Scholar
  3. S. Riaz, “Diabetes mellitus,” Scientific Research and Essays, vol. 4, no. 5, pp. 367–373, 2009. View at Google Scholar · View at Scopus
  4. WHO, Requirements of Vitamin A, Thiamine, Riboflavine and Niacin. Report of a Joint FAO/WHO Expert Group, WHO Technical Report Series no. 362, World Health Organization, Geneva, Switzerland, 1967.
  5. R. Frank and R. Hargreaves, “Clinical biomarkers in drug discovery and development,” Nature Reviews Drug Discovery, vol. 2, no. 7, pp. 566–580, 2003. View at Publisher · View at Google Scholar · View at Scopus
  6. G. Ferber, “Biomarkers and proof of concept,” Methods and Findings in Experimental and Clinical Pharmacology, vol. 24, pp. 35–40, 2002. View at Google Scholar · View at Scopus
  7. E. Betgovargez and M. H. Simonian, “Reproducibility and dynamic range characteristics of the ProteomeLab PF2D system,” Beckman Coulter Application Information Bulletin A-1964, 2003. View at Google Scholar
  8. R. Aebersold and M. Mann, “Mass spectrometry-based proteomics,” Nature, vol. 422, no. 6928, pp. 198–207, 2003. View at Publisher · View at Google Scholar · View at Scopus
  9. W. L. Lowe, Principles of Molecular Medicine, Humana Press, New Jersey, NJ, USA, 16th edition, 2005.
  10. M. Brownlee, “Biochemistry and molecular cell biology of diabetic complications,” Nature, vol. 414, no. 6865, pp. 813–820, 2001. View at Publisher · View at Google Scholar · View at Scopus
  11. H. P. Himsworth, “Diabetes mellitus: its differentiation into insulin-sensitive and insulin-insensitive types,” The Lancet, vol. 227, no. 5864, pp. 127–130, 1936. View at Publisher · View at Google Scholar · View at Scopus
  12. V. Thongboonkerd, “Current status of renal and urinary proteomics: ready for routine clinical application,” Nephrology Dialysis Transplantation, vol. 25, no. 1, pp. 11–16, 2010. View at Publisher · View at Google Scholar · View at Scopus
  13. R. Pieper, C. L. Gatlin, A. J. Makusky et al., “The human serum proteome: display of nearly 3700 chromatographically separated protein spots on two-dimensional electrophoresis gels and identification of 325 distinct proteins,” Proteomics, vol. 3, no. 7, pp. 1345–1364, 2003. View at Publisher · View at Google Scholar · View at Scopus
  14. M. H. Simonian and E. Betgovargez, Proteome Analysis of Human Plasma with ProteomeLab PF2D System, A-1969-A, Beckman Coulter, Inc., 2005.
  15. J. Y. Kim, J. H. Lee, G. W. Park et al., “Utility of electrophoretically derived protein mass estimates as additional constraints in proteome analysis of human serum based on MS/MS analysis,” Proteomics, vol. 5, no. 13, pp. 3376–3385, 2005. View at Publisher · View at Google Scholar · View at Scopus
  16. M. A. Clay, D. A. Cehic, D. H. Pyle, K.-A. Rye, and P. J. Barter, “Formation of apolipoprotein-specific high-density lipoprotein particles from lipid-free apolipoproteins A-I and A-II,” Biochemical Journal, vol. 337, no. 3, pp. 445–451, 1999. View at Publisher · View at Google Scholar · View at Scopus
  17. F. Wang, O.-F. Xia, and S.-F. Sui, “Human apolipoprotein H may have various orientations when attached to lipid layer,” Biophysical Journal, vol. 83, no. 2, pp. 985–993, 2002. View at Publisher · View at Google Scholar · View at Scopus
  18. P. E. Richardson, M. Manchekar, N. Dashti et al., “Assembly of lipoprotein particles containing apolipoprotein-B: structural model for the nascent lipoprotein particle,” Biophysical Journal, vol. 88, no. 4, pp. 2789–2800, 2005. View at Publisher · View at Google Scholar · View at Scopus
  19. K. Bach-Ngohou, K. Ouguerram, H. Nazih et al., “Apolipoprotein E kinetics: influence of insulin resistance and type 2 diabetes,” International Journal of Obesity, vol. 26, no. 11, pp. 1451–1458, 2002. View at Publisher · View at Google Scholar · View at Scopus
  20. I. P. Trougakos, M. Poulakou, M. Stathatos, A. Chalikia, A. Melidonis, and E. S. Gonos, “Serum levels of the senescence biomarker clusterin/apolipoprotein J increase significantly in diabetes type II and during development of coronary heart disease or at myocardial infarction,” Experimental Gerontology, vol. 37, no. 10-11, pp. 1175–1187, 2002. View at Publisher · View at Google Scholar · View at Scopus
  21. T. Nakanishi, R. Koyama, T. Ikeda, and A. Shimizu, “Catalogue of soluble proteins in the human vitreous humor: comparison between diabetic retinopathy and macular hole,” Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, vol. 776, no. 1, pp. 89–100, 2002. View at Publisher · View at Google Scholar · View at Scopus
  22. W. Borth, “α2-macroglobulin, a multifunctional binding protein with targeting characteristics,” The FASEB Journal, vol. 6, no. 15, pp. 3345–3353, 1992. View at Google Scholar · View at Scopus
  23. Y. Itoh, H. Enomoto, K. Takagi, T. Kawai, and T. Yamanaka, “Human alpha1-microglobulin in various hepatic disorders,” Digestion, vol. 27, no. 2, pp. 75–80, 1983. View at Publisher · View at Google Scholar · View at Scopus
  24. P. V. Rao, A. Reddy, and X. Lu, “Transthyretin and it's miracle function and pathogenesis,” Journal of Proteome Research, vol. 8, pp. 239–245, 2009. View at Google Scholar
  25. S. K. James, B. Lindahl, J. R. Timmer et al., “Usefulness of biomarkers for predicting long-term mortality in patients with diabetes mellitus and non-ST-elevation acute coronary syndromes (a GUSTO IV substudy),” The American Journal of Cardiology, vol. 97, no. 2, pp. 167–172, 2006. View at Google Scholar
  26. C. F. Semenkovich, S.-H. Chen, M. Wims, C.-C. Luo, W.-H. Li, and L. Chan, “Lipoprotein lipase and hepatic lipase mRNA tissue specific expression, developmental regulation, and evolution,” Journal of Lipid Research, vol. 30, no. 3, pp. 423–431, 1989. View at Google Scholar · View at Scopus
  27. D. T. Graves and D. Cochran, “The contribution of interleukin-1 and tumor necrosis factor to periodontal tissue destruction,” Journal of Periodontology, vol. 74, no. 3, pp. 391–401, 2003. View at Publisher · View at Google Scholar · View at Scopus
  28. L. A. Campfield, F. J. Smith, and P. Burn, “The OB protein (leptin) pathway—a link between adipose tissue mass and central neural networks,” Hormone and Metabolic Research, vol. 28, no. 12, pp. 619–632, 1996. View at Publisher · View at Google Scholar · View at Scopus
  29. D. A. A. Myles, S. A. Rule, L. J. DeLucas et al., “Rotation function studies of human C-reactive protein. Lipid, Lipoproteins, C-Reactive Protein, and Hemostatic Factors at Baseline in the Diabetes Prevention Program,” Journal of Molecular Biology, vol. 216, no. 3, pp. 491–496, 1990. View at Publisher · View at Google Scholar · View at Scopus
  30. R. S. Lindsay, T. Funahashi, R. L. Hanson et al., “Adiponectin and development of type 2 diabetes in the Pima Indian population,” The Lancet, vol. 360, no. 9326, pp. 57–58, 2002. View at Publisher · View at Google Scholar · View at Scopus
  31. P. Martín-Gallán, A. Carrascosa, M. Gussinyé, and C. Domínguez, “Biomarkers of diabetes-associated oxidative stress and antioxidant status in young diabetic patients with or without subclinical complications,” Free Radical Biology and Medicine, vol. 34, no. 12, pp. 1563–1574, 2003. View at Publisher · View at Google Scholar · View at Scopus
  32. E. García-Rubi and J. Calles-Escandón, “Insulin resistance and type 2 diabetes mellitus: its relationship with the β3-adrenergic receptor,” Archives of Medical Research, vol. 30, no. 6, pp. 459–464, 1999. View at Publisher · View at Google Scholar · View at Scopus
  33. M. Oh-Ishi, T. Ueno, and T. Maeda, “Proteomic method detects oxidatively induced protein carbonyls in muscles of a diabetes model Otsuka Long-Evans Tokushima Fatty (OLETF) rat,” Free Radical Biology and Medicine, vol. 34, no. 1, pp. 11–22, 2003. View at Publisher · View at Google Scholar · View at Scopus
  34. A. Festa, R. D'Agostino Jr., R. P. Tracy, and S. M. Haffner, “Elevated levels of acute-phase proteins and plasminogen activator inhibitor-1 predict the development of type 2 diabetes: the insulin resistance atherosclerosis study,” Diabetes, vol. 51, no. 4, pp. 1131–1137, 2002. View at Google Scholar
  35. A. F. Mark, “Intramuscular heat shock protein 72 and heme oxygenase-1 mRNA are reduced in patients with type 2 diabetes: evidence that insulin resistance is associated with a disturbed antioxidant defense mechanism,” Diabetes, vol. 52, no. 9, pp. 2338–2345, 2003. View at Google Scholar
  36. D. Bassoa, E. Grecoa, P. Fogara, P. Puccib, A. Flagiellob, and M. Plebania, “Pancreatic cancer-associated diabetes mellitus: an open field for proteomic applications,” Clinica Chimica Acta, vol. 357, no. 2, pp. 184–189, 2005. View at Google Scholar
  37. S. Riaz, S. S. Alam, M. Raza, S. Hasnain, and M. W. Akhtar, “Obesity as risk factor and study of obesity related proteins in diabetes mellitus,” African Journal of Biotechnology, vol. 8, no. 5, pp. 737–744, 2009. View at Google Scholar · View at Scopus
  38. Q. Yang, T. E. Graham, N. Mody et al., “Serum retinol binding protein 4 contributes to insulin resistance in obesity and type 2 diabetes,” Nature, vol. 436, no. 7049, pp. 356–362, 2005. View at Publisher · View at Google Scholar · View at Scopus
  39. T. O. Metz, W.-J. Qian, J. M. Jacobs et al., “Application of proteomics in the discovery of candidate protein biomarkers in a diabetes autoantibody standardization program sample subset,” Journal of Proteome Research, vol. 7, no. 2, pp. 698–707, 2008. View at Publisher · View at Google Scholar · View at Scopus
  40. H. Jiang, G. Guan, R. Zhang et al., “Identification of urinary soluble E-cadherin as a novel biomarker for diabetic nephropathy,” Diabetes/Metabolism Research and Reviews, vol. 25, no. 3, pp. 232–241, 2009. View at Publisher · View at Google Scholar · View at Scopus
  41. N. K. Shinton, R. W. Richradson, and J. D. F. Williams, “Diagnostic value of serum haptoglobin,” Journal of Clinical Pathology, vol. 18, pp. 114–118, 1965. View at Publisher · View at Google Scholar · View at Scopus